| Name | Title | Contact Details |
|---|
Since 1992, Omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. Omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. Our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. Omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs. Omnicell has been recognized with KLAS awards every year since 2005.
Drive DeVilbiss is committed to bringing to market a superior suite of products that focuses on innovation and design while improving the quality of life and promoting the independence for the individuals that use our durable medical equipment. Drive is dedicated to their customers by continually offering the highest quality and most functional products across a broad spectrum of health care needs, products that are a better value and competitively priced delivered by a team of world-class professionals. Drive’s complete line of products enhances the life of each user, from the mobility, bariatric, pressure prevention, self-assist, rehabilitation, pediatric products, to our wheelchairs, sleep surfaces, beds, respiratory equipment, power scooters, patient room equipment, to our electrotherapy devices and personal care products. We are the fastest growing global manufacturers of durable medical equipment; our products are used and distributed throughout North America, Europe, Central America, South America, the Middle East and Asia. Our market spans many verticals including: home healthcare providers, healthcare distributors, retailers, and e-tailers. Our recent expansion includes a new Long-Term Care Division and a new Acute Care Division. These developments are accompanied by the continued growth in the core home health care business. The corporate and distribution offices extend across the United States, Canada, United Kingdom, Germany, Romania, China and Taiwan.
NOWDiagnostics Inc., based in Springdale, Ark., is a leader in innovative diagnostics testing. Its ADEXUSDx™ product line features a lab at your fingertip, using only a single drop of blood to test for a variety of common conditions, illnesses and diseases with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics has the potential to decrease by days the waiting period to determine test results. The company is currently offering an hCG (pregnancy) test in the United States and Europe, and two cardiac (heart attack) tests and three toxicology tests in Europe. Additional tests are in the development pipeline, including sexually transmitted diseases, more cardiac (heart attack), food intolerances, common infectious diseases and a variety of screening tests.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.
PrimaPharm is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.